HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Hinkle, R. T. Articles by Isfort, R. J. Search for Related Content PubMed PubMed Citation Articles by Hinkle, R. T. Articles by Isfort, R. J.

Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions

¹Procter & Gamble Pharmaceuticals, Mason, Ohio 45040-9317; ²McMaster University, Hamilton, Ontario, Canada L8N 3Z5; and ³Oregon Health Sciences University, Portland, Oregon 97201

Submitted 20 February 2003 ; accepted in final form 27 May 2003

Two receptors activated by the corticotropin-releasing factor (CRF) family of peptides have been identified, the CRF 1 receptor (CRF1R) and the CRF 2 receptor (CRF2R). Of these, the CRF2R is expressed in skeletal muscle. To understand the role of the CRF2R in skeletal muscle, we utilized CRFR knockout mice and CRF2R-selective agonists to modulate nerve damage and corticosteroid- and disuse-induced skeletal muscle atrophy in mice. These analyses demonstrated that activation of the CRF2R decreased nerve damage and corticosteroid- and disuse-induced skeletal muscle mass and function loss. In addition, selective activation of the CRF2R increased nonatrophy skeletal muscle mass. Thus we describe for the first time a novel activity of the CRF2R, modulation of skeletal muscle mass.

atrophy; hypertrophy; corticotropin-releasing factor receptor; sauvagine; urocortin II